Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 552.12 Thousand USD | 116.52% |
| 2023 | 255 Thousand USD | 141.91% |
| 2022 | 105.41 Thousand USD | -85.97% |
| 2021 | 751.43 Thousand USD | 23250.99% |
| 2020 | 3218.00 USD | -97.55% |
| 2019 | 131.47 Thousand USD | 12.37% |
| 2018 | 116.99 Thousand USD | -87.0% |
| 2017 | 899.76 Thousand USD | -35.79% |
| 2016 | 1.4 Million USD | 49.46% |
| 2015 | 937.6 Thousand USD | 715.26% |
| 2014 | 115 Thousand USD | 1934.8% |
| 2013 | 5652.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 552.12 Thousand USD | -13.91% |
| 2024 Q1 | 78.92 Thousand USD | -69.05% |
| 2024 FY | 552.12 Thousand USD | 116.52% |
| 2024 Q3 | 641.29 Thousand USD | -38.49% |
| 2024 Q2 | 1.04 Million USD | 1221.13% |
| 2023 Q2 | 1.2 Million USD | 555.12% |
| 2023 FY | 255 Thousand USD | 141.91% |
| 2023 Q4 | 255 Thousand USD | -54.93% |
| 2023 Q3 | 565.84 Thousand USD | -52.89% |
| 2023 Q1 | 183.32 Thousand USD | 73.91% |
| 2022 Q2 | 105.42 Thousand USD | -61.79% |
| 2022 Q3 | 751.73 Thousand USD | 613.06% |
| 2022 FY | 105.41 Thousand USD | -85.97% |
| 2022 Q4 | 105.41 Thousand USD | -85.98% |
| 2022 Q1 | 275.87 Thousand USD | -63.29% |
| 2021 Q3 | 72.98 Thousand USD | -26.42% |
| 2021 Q2 | 99.19 Thousand USD | 22862.5% |
| 2021 Q1 | 432.00 USD | -86.58% |
| 2021 FY | 751.43 Thousand USD | 23250.99% |
| 2021 Q4 | 751.43 Thousand USD | 929.57% |
| 2020 Q2 | 5471.00 USD | 1.73% |
| 2020 FY | 3218.00 USD | -97.55% |
| 2020 Q1 | 5378.00 USD | -95.91% |
| 2020 Q4 | 3218.00 USD | 76.91% |
| 2020 Q3 | 1819.00 USD | -66.75% |
| 2019 Q3 | 103.3 Thousand USD | -6.23% |
| 2019 Q1 | 49.14 Thousand USD | -58.0% |
| 2019 FY | 131.47 Thousand USD | 12.37% |
| 2019 Q2 | 110.17 Thousand USD | 124.2% |
| 2019 Q4 | 131.47 Thousand USD | 27.27% |
| 2018 Q3 | 803.76 Thousand USD | -37.98% |
| 2018 FY | 116.99 Thousand USD | -87.0% |
| 2018 Q2 | 1.29 Million USD | 40.12% |
| 2018 Q1 | 924.89 Thousand USD | 2.79% |
| 2018 Q4 | 116.99 Thousand USD | -85.44% |
| 2017 Q1 | 893.18 Thousand USD | -36.26% |
| 2017 Q4 | 899.76 Thousand USD | 2.29% |
| 2017 FY | 899.76 Thousand USD | -35.79% |
| 2017 Q3 | 879.59 Thousand USD | -34.86% |
| 2017 Q2 | 1.35 Million USD | 51.18% |
| 2016 Q2 | 871.94 Thousand USD | -7.26% |
| 2016 Q1 | 940.21 Thousand USD | 0.28% |
| 2016 FY | 1.4 Million USD | 49.46% |
| 2016 Q4 | 1.4 Million USD | 67.94% |
| 2016 Q3 | 834.41 Thousand USD | -4.3% |
| 2015 FY | 937.6 Thousand USD | 715.26% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 937.6 Thousand USD | 211.2% |
| 2015 Q2 | 77.73 Thousand USD | 0.0% |
| 2015 Q3 | 301.28 Thousand USD | 287.6% |
| 2014 Q4 | 115 Thousand USD | 0.0% |
| 2014 FY | 115 Thousand USD | 1934.8% |
| 2013 FY | 5652.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -23801.299% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 71.805% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 94.769% |
| Rebus Holdings, Inc. | 5000.00 USD | -10942.4% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.576% |
| Qrons Inc. | 420.00 USD | -131357.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 28.356% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.024% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -14.892% |
| Skye Bioscience, Inc. | 11.94 Million USD | 95.376% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.579% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 92.353% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -623.106% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.485% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 61.445% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -662.966% |
| Mesoblast Limited | 667.9 Million USD | 99.917% |
| Marizyme, Inc. | 22.01 Million USD | 97.492% |
| Genus plc | 1.02 Billion USD | 99.946% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 59.354% |
| Pharming Group N.V. | 462.85 Million USD | 99.881% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 83.335% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -10.637% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 11.943% |
| ContraFect Corporation | 20.67 Million USD | 97.33% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -41.436% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -44.467% |
| IMV Inc. | 31.33 Million USD | 98.238% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 86.683% |
| MultiCell Technologies, Inc. | 126.22 USD | -437326.715% |
| ONE Bio Corp. | 70.08 Million USD | 99.212% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 41.244% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.57% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -27.89% |
| Q BioMed Inc. | 3.51 Million USD | 84.295% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.431% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -111.316% |
| Biomind Labs Inc. | 73.81 Thousand USD | -647.938% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.876% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 61.892% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.161% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 79.896% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 19.69% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 78.791% |
| GB Sciences, Inc. | 103.44 Thousand USD | -433.748% |
| Alpha Cognition Inc. | 2.45 Million USD | 77.484% |
| HST Global, Inc. | 1526.00 USD | -36080.865% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 44.116% |
| Halberd Corporation | 10.13 Thousand USD | -5349.808% |
| Enzolytics Inc. | 361.7 Million USD | 99.847% |
| Agentix Corp. | 261.39 Thousand USD | -111.223% |
| Resverlogix Corp. | 8.11 Million USD | 93.196% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 70.599% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.843% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 13.685% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2323.599% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 93.83% |
| AVAX Technologies, Inc. | 7.37 Million USD | 92.516% |
| Zenith Capital Corp. | 7410.00 USD | -7351.012% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.984% |
| Ember Therapeutics, Inc. | 184.00 USD | -299965.217% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -71.569% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -111.246% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 40.502% |
| Kadimastem Ltd | 2.3 Million USD | 76.037% |
| Helix BioMedix, Inc. | 3.02 Million USD | 81.749% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 98.952% |
| BioStem Technologies, Inc. | 14.56 Million USD | 96.208% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -867.037% |
| LadRx Corporation | 2.3 Million USD | 76.077% |
| Cell Source, Inc. | 195.17 Thousand USD | -182.89% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -56.135% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -56.135% |
| NovAccess Global Inc. | 62.24 Thousand USD | -786.968% |
| Affymax, Inc. | 7.44 Million USD | 92.582% |
| Itoco Inc. | 1.4 Million USD | 60.565% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -477.187% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -420.868% |
| Mobile Lads Corp. | 52.00 USD | -1061669.231% |
| CytoDyn Inc. | 11.13 Million USD | 95.042% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -286.174% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2987.919% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -43.233% |
| SYBLEU INC | 330.46 Thousand USD | -67.072% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -34.854% |
| International Stem Cell Corporation | 5.39 Million USD | 89.757% |
| Bioxytran, Inc. | 137.63 Thousand USD | -301.139% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 96.32% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 96.67% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -598.886% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 36.147% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 92.655% |
| Neutra Corp. | 2851.00 USD | -19265.837% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.296% |
| PureTech Health plc | 693.97 Million USD | 99.92% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 93.159% |
| IXICO plc | 15.84 Million USD | 96.515% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 93.333% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.466% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.835% |